Offer Request Form

Order list is empty

Shikari® (S-ATR) Anti-Rituximab ELISA w/confirmation

Enzyme immunoassay for the quantitative determination of antibodies to of Rituximab (Rituxan®, Mabthera®) in serum and plasma with confirmation.

This kit has been especially developed for the quantitative antibodies to Rituximab in serum and plasma samples

Rituximab (Rituxan®, Mabthera®) was associated to the development of anti-rituximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug (Rituxan®, Mabthera®)  .This might lead to severe complications. This kit can be efficiently used for monitoring anti- rituximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-rituximab antibodies. 

All SHIKARI® ELISA kits are suitable for biosimilar work. 

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact

Required Volume (µl) 10
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 7,5
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download
Validation Report Download

Publications with this drug

# File Action
Sinha, Aditi, et al. "Sequential rituximab therapy sustains remission of nephrotic syndrome, but carries high risk of adverse effects." Nephrology Dialysis Transplantation (2022). Visit Link
Chen, Yewei, et al. "Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome." Frontiers in Pharmacology (2021): 2348. Visit Link
Liu, Shu, et al. "Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes." Clinical and Translational Science (2021). Visit Link
Liu, Shu, et al. "Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2." Acta Pharmacologica Sinica (2020): 1-7. Visit Link
Bai Y, Li W, Yan C, Hou Y, Wang Q. Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody. Front Immunol. 2023 Mar 28;14:1121705. Visit Link